467 Matching Annotations
  1. Dec 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, S1473309921006800. https://doi.org/10.1016/S1473-3099(21)00680-0

  2. Nov 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0

    1. Seth Trueger. (2021, July 21). If seatbelts work so well why do we have airbags crumple zones speed limits licensing road signs traffic lights road safety engineering ambulances EMTs trauma centers brakes https://t.co/6x29wCOlwp [Tweet]. @MDaware. https://twitter.com/MDaware/status/1417680529160294401

    1. WHO/Europe. (2021, October 19). Are you a Mask Master? 😷 Take this quick quiz to find out 👉 https://bit.ly/3jbn5iS Wearing a well-fitted mask, along with practicing other prevention measures, is an important part of slowing the spread of #COVID19 High quiz scores = Mask Master badge 🎖 https://t.co/0PzSsgsBfD [Tweet]. @WHO_Europe. https://twitter.com/WHO_Europe/status/1450451677098790916

    1. Dr Nisreen Alwan 🌻. (2021, October 30). Mass infection of kids with a virus less than 2 years old is not ethical, not moral, not scientifically evidenced, not socially just & medically risky. There’s no good argument for this. And no, boosting population immunity to protect the adults is not a valid argument. #Childism [Tweet]. @Dr2NisreenAlwan. https://twitter.com/Dr2NisreenAlwan/status/1454498829403922440

    1. ReconfigBehSci. (2021, November 1). 2/2 from the paper ‘We speculate that the extraordinarily high antibody titers observed in vaccinated individuals who develop breakthrough infections may lead to subsequent long-term protection in those individuals.’ [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1455104597454954497

    1. Deepti Gurdasani. (2021, November 1). No- the statement explicitly talks about infection in children being a ‘booster’ to adults i.e. Children infecting adults to protect them against... Infection!🤔 I don’t think there’s any level of cognitive gymnastics that could justify this or make sense of it. [Tweet]. @dgurdasani1. https://twitter.com/dgurdasani1/status/1455106192112500736

  3. Oct 2021
    1. Gil Feldman. (2021, October 26). @EricTopol Updated data from Israel. The booster works, without any doubt! Red (empty battery): Un-vax Light green (half battery): 2nd dose without the booster Green (full battery): With the booster https://t.co/HbZBvDMQs6 [Tweet]. @feldman_gil. https://twitter.com/feldman_gil/status/1452845319251767299

    1. Hulme, W. J., Williamson, E. J., Green, A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., Tomlinson, L., Palmer, T., Horne, E., MacKenna, B., Morton, C. E., Mehrkar, A., Fisher, L., Bacon, S., Evans, D., … Goldacre, B. (2021). Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: A cohort study using OpenSAFELY [Preprint]. Epidemiology. https://doi.org/10.1101/2021.10.13.21264937

    1. Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., Loney, C., Herder, V., Allan, J., Jarmson, I., Cameron-Ruiz, N., Varjak, M., Pinto, R. M., Lee, J. Y., Iselin, L., Palmalux, N., Stewart, D. G., Swingler, S., Greenwood, E. J. D., … Wilson, S. J. (n.d.). A prenylated dsRNA sensor protects against severe COVID-19. Science, 0(0), eabj3624. https://doi.org/10.1126/science.abj3624

    1. Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S. A., Baidya, A., Nande, A. A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., Patel, M. K., Knoll, M. D., & Hill, A. L. (2021). A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease [Preprint]. Epidemiology. https://doi.org/10.1101/2021.09.17.21263549

  4. Sep 2021
    1. Liu, W., Russell, R. M., Bibollet-Ruche, F., Skelly, A. N., Sherrill-Mix, S., Freeman, D. A., Stoltz, R., Lindemuth, E., Lee, F.-H., Sterrett, S., Bar, K. J., Erdmann, N., Gouma, S., Hensley, S. E., Ketas, T., Cupo, A., Cruz Portillo, V. M., Moore, J. P., Bieniasz, P. D., … Hahn, B. H. (2021). Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging Infectious Diseases, 27(9), 2454–2458. https://doi.org/10.3201/eid2709.211042

  5. Aug 2021
    1. Liu, Y., Arase, N., Kishikawa, J., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., Jin, H., Kishida, K., Nakai, W., Kohyama, M., Nakagawa, A., Yamagishi, Y., Nakagami, H., Kumanogoh, A., Matsuura, Y., … Arase, H. (2021). The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines (p. 2021.08.22.457114). https://doi.org/10.1101/2021.08.22.457114

    1. John Burn-Murdoch. (2021, May 27). NEW: B.1617.2 is fuelling a third wave in the UK, with not only cases but also hospital admissions rising. Vaccines will make this wave different to those that have come before, but it remains a concern, and one that other countries will soon face. Thread on everything we know: Https://t.co/4825qOqgrl [Tweet]. @jburnmurdoch. https://twitter.com/jburnmurdoch/status/1397995388267810818

  6. Jul 2021
  7. Jun 2021
    1. Helen McArdle on Twitter: “The good news: An astonishing 98.2% of over-60s in Scotland are now fully vaccinated. That’s an amazing uptake. It doesn’t mean they are 100% protected of course (and especially not when case rates are high) but their risk of hospitalisation/death is cut by over 90% https://t.co/DzAxkpLvcR” / Twitter. (n.d.). Retrieved June 30, 2021, from https://twitter.com/HMcArdleHT/status/1409821893557768195

    1. Knock, E. S., Whittles, L. K., Lees, J. A., Perez-Guzman, P. N., Verity, R., FitzJohn, R. G., Gaythorpe, K. A. M., Imai, N., Hinsley, W., Okell, L. C., Rosello, A., Kantas, N., Walters, C. E., Bhatia, S., Watson, O. J., Whittaker, C., Cattarino, L., Boonyasiri, A., Djaafara, B. A., … Baguelin, M. (2021). Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England. Science Translational Medicine, eabg4262. https://doi.org/10.1126/scitranslmed.abg4262

    1. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., … Gaglani, M. (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers—Eight U.S. Locations, December 2020–March 2021. MMWR. Morbidity and Mortality Weekly Report, 70(13), 495–500. https://doi.org/10.15585/mmwr.mm7013e3

    1. Parry, H. M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D’Arcangelo, S., … Moss, P. (2021). BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3816840

    1. Was there any domestic abuse in your family?Luisa: With my parents? My mother, yes. She doesn't like to talk about it. The older I get, the more she opens up, but it's not something that she likes to talk about. It was never in front of us, it was behind closed doors. I thank my father. He's a piece of shit, but I thank him for at least having the thought of not wanting to traumatize us. So yes, it was behind closed doors, but the more I get out of my mom, it was a lot of emotional abuse as well, a lot. I think there was some physical abuse. My mom's never touched upon it, but that's what happened.

      Time in the US, Migration from Mexico, Reasons, Domestic Violence

  8. May 2021
    1. Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422

    1. Sam Bowman. (2021, January 25). If the govt can’t keep a few thousand people fed in hotel quarantine, how exactly was it supposed to provide for fifteen million pensioners self-isolating in Great Barrington-style ‘focused protection’ while the virus was spreading across the rest of the population? [Tweet]. @s8mb. https://twitter.com/s8mb/status/1353666214883684352

    1. Howard, J., Huang, A., Li, Z., Tufekci, Z., Zdimal, V., Westhuizen, H.-M. van der, Delft, A. von, Price, A., Fridman, L., Tang, L.-H., Tang, V., Watson, G. L., Bax, C. E., Shaikh, R., Questier, F., Hernandez, D., Chu, L. F., Ramirez, C. M., & Rimoin, A. W. (2021). An evidence review of face masks against COVID-19. Proceedings of the National Academy of Sciences, 118(4). https://doi.org/10.1073/pnas.2014564118

    1. Jonathan Rothberg 🦋. (2021, March 2). Testing works. I test daily. Insist on HOME testing. @michaelmina_lab @JoeBiden Research suggests B.1.526 needs to be closely watched “for its ability to evade both monoclonal antibody and, to a certain extent, the vaccine-induced antibody,” said Fauci [Tweet]. @JMRothberg. https://twitter.com/JMRothberg/status/1366755339912306688

  9. Apr 2021
  10. Mar 2021
    1. “Follow your blisters” implies something that you come back to so many times that you eventually move past the blister stage, into toughened skin. Eventually, the activity “marks you” through use and practice, and you develop a special competence. When you practice an activity a bit more obsessively than other people, you build unique character – you earn some wear and some healing that makes you idiosyncratic, and a little unbalanced.It is something that you don’t need to put on your to-do list, something you care enough about to return to repeatedly, even though it causes discomfort. Over time, you develop a layer of protection that enables you to do that something more easily.
  11. Feb 2021
  12. Jan 2021
  13. Nov 2020
    1. Identify, classify, and apply protective measures to sensitive data. Data discovery and data classification solutions help to identify sensitive data and assign classification tags dictating the level of protection required. Data loss prevention solutions apply policy-based protections to sensitive data, such as encryption or blocking unauthorized actions, based on data classification and contextual factors including file type, user, intended recipient/destination, applications, and more. The combination of data discovery, classification, and DLP enable organizations to know what sensitive data they hold and where while ensuring that it's protected against unauthorized loss or exposure.

      [[BEST PRACTICES FOR DATA EGRESS MANAGEMENT AND PREVENTING SENSITIVE DATA LOSS]]

  14. Oct 2020
  15. Sep 2020
    1. Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., Chia, W. N., Chen, M. I.-C., Wang, L.-F., Ooi, E. E., Kalimuddin, S., Tambyah, P. A., Low, J. G.-H., Tan, Y.-J., & Bertoletti, A. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 584(7821), 457–462. https://doi.org/10.1038/s41586-020-2550-z

  16. Aug 2020
    1. Felipe, L. S., Vercruysse, T., Sharma, S., Ma, J., Lemmens, V., Looveren, D. van, Javarappa, M. P. A., Boudewijns, R., Malengier-Devlies, B., Kaptein, S. F., Liesenborghs, L., Keyzer, C. D., Bervoets, L., Rasulova, M., Seldeslachts, L., Jansen, S., Yakass, M. B., Quaye, O., Li, L.-H., … Dallmeier, K. (2020). A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate. BioRxiv, 2020.07.08.193045. https://doi.org/10.1101/2020.07.08.193045

    1. Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 1–8. https://doi.org/10.1038/s41586-020-2622-0

    1. Chen, Y., Yang, W.-H., Huang, L.-M., Wang, Y.-C., Yang, C.-S., Liu, Y.-L., Hou, M.-H., Tsai, C.-L., Chou, Y.-Z., Huang, B.-Y., Hung, C.-F., Hung, Y.-L., Chen, J.-S., Chiang, Y.-P., Cho, D.-Y., Jeng, L.-B., Tsai, C.-H., & Hung, M.-C. (2020). Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro. BioRxiv, 2020.08.14.250258. https://doi.org/10.1101/2020.08.14.250258

    1. Kreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., Trimpert, J., Höltje, M., Dietert, K., Stöffler, L., Wardenburg, N. von, Hoof, S. van, Homeyer, M. A., Hoffmann, J., Abdelgawad, A., … Prüss, H. (2020). A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model. BioRxiv, 2020.08.15.252320. https://doi.org/10.1101/2020.08.15.252320

    1. Sun, W., McCroskery, S., Liu, W.-C., Leist, S. R., Liu, Y., Albrecht, R. A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., Dinnon, K. H., Innis, B. L., García-Sastre, A., Krammer, F., Baric, R. S., & Palese, P. (2020). A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. BioRxiv, 2020.07.30.229120. https://doi.org/10.1101/2020.07.30.229120